A novel approach to immunotherapy developed by researchers at the National Cancer Institute (NCI) has led to the complete regression of breast cancer in a patient who was unresponsive to all other treatments.
This patient received the treatment in a clinical trial led by Steven A. Rosenberg, M.D., Ph.D., chief of the Surgery Branch at NCI’s Center for Cancer Research (CCR), and the findings were published June 4, 2018 in Nature Medicine. NCI is part of the National Institutes of Health.
“We’ve developed a high-throughput method to identify mutations present in a cancer that are recognized by the immune system,” Dr. Rosenberg said. “This research is experimental right now. But because this new approach to immunotherapy is dependent on mutations, not on cancer type, it is in a sense a blueprint we can use for the treatment of many types of cancer.”
The new immunotherapy approach is a modified form of adoptive cell transfer (ACT). ACT has been effective in treating melanoma, which has high levels of somatic, or acquired, mutations. However, it has been less effective with some common epithelial cancers, or cancers that start in the lining of organs, that have lower levels of mutations, such as stomach, esophageal, ovarian, and breast cancers.
In an ongoing phase 2 clinical trial, the investigators are developing a form of ACT that uses tumor-infiltrating lymphocytes (TILs) that specifically target tumor cell mutations to see if they can shrink tumors in patients with these common epithelial cancers. As with other forms of ACT, the selected TILs are grown to large numbers in the laboratory and are then infused back into the patient (who has in the meantime undergone treatment to deplete remaining lymphocytes) to create a stronger immune response against the tumor.
A patient with metastatic breast cancer came to the trial after receiving multiple treatments, including several chemotherapy and hormonal treatments, that had not stopped her cancer from progressing. To treat her, the researchers sequenced DNA and RNA from one of her tumors, as well as normal tissue to see which mutations were unique to her cancer, and identified 62 different mutations in her tumor cells.
The researchers then tested different TILs from the patient to find those that recognized one or more of these mutated proteins. TILs recognized four of the mutant proteins, and the TILs then were expanded and infused back into the patient. She was also given the checkpoint inhibitor pembrolizumab to prevent the possible inactivation of the infused T cells by factors in the tumor microenvironment. After the treatment, all of this patient’s cancer disappeared and has not returned more than 22 months later.
“This is an illustrative case report that highlights, once again, the power of immunotherapy,” said Tom Misteli, Ph.D., director of CCR at NCI. “If confirmed in a larger study, it promises to further extend the reach of this T-cell therapy to a broader spectrum of cancers.”
Investigators have seen similar results using mutation-targeted TIL treatment for patients in the same trial with other epithelial cancers, including liver cancer and colorectal cancer. Dr. Rosenberg explained that results like this in patients with solid epithelial tumors are important because ACT has not been as successful with these kinds of cancers as with other types that have more mutations.
He said the “big picture” here is this kind of treatment is not cancer-type specific. “All cancers have mutations, and that’s what we’re attacking with this immunotherapy,” he said. “It is ironic that the very mutations that cause the cancer may prove to be the best targets to treat the cancer.”
The Latest on: Cancer immunotherapy
[google_news title=”” keyword=”cancer immunotherapy” num_posts=”10″ blurb_length=”0″ show_thumb=”left”]
via Google News
The Latest on: Cancer immunotherapy
- Cancer Vaccine Tested in Glioblastoma Patients Shows Potential of mRNA Aggregateson May 1, 2024 at 7:05 pm
Vaccine harnesses multi-lamellar LP aggregates (LPA) that can simultaneously function as vaccines and as immunomodulating agents.
- New mRNA cancer vaccine triggers fierce immune response to fight malignant brain tumoron May 1, 2024 at 5:16 pm
An mRNA cancer vaccine quickly reprogrammed the immune system to attack the most aggressive type of brain tumor in a first-ever human clinical trial.
- Brain cancer in children is notoriously hard to treat – a new mRNA cancer vaccine triggers an attack from withinon May 1, 2024 at 9:05 am
Cancer vaccines have gained much interest among scientists but face a number of hurdles. A new mRNA vaccine for glioma offers a step forward in training the immune system to fight cancer.
- Researchers find difference in pancreatic cancer cells, offering new hope for immunotherapy effectivenesson May 1, 2024 at 6:32 am
A new study has found that pancreatic cancer cells are different based on their location ... of tumors in the pancreatic head versus the body and tail, particularly the immunotherapy receptors found ...
- Unlocking the immune system: cGAS-STING pathway offers new hope for cancer treatmenton April 30, 2024 at 10:38 am
Cancer immunotherapy, which leverages the body's immune system to target tumors, has emerged as a pivotal strategy in oncology. This paradigm shift from conventional treatments offers a more precise ...
- Breaking: AI Could Transform Cancer Treatment by Predicting Immunotherapy Successon April 30, 2024 at 8:27 am
In this article, we’ll explore a breakthrough development in the fight against cancer: how artificial intelligence (AI) is poised to predict immunotherapy success. This has the potential to ...
- Immunotherapy: A Beacon of Hope in Cancer Treatmenton April 29, 2024 at 11:38 pm
Cancer, a disease that has plagued humanity for centuries, has finally met its match in immunotherapy, a revolutionary treatment that harnesses the power of the immune system to combat this deadly ...
- Cancer immunity gets a boost from one common nutrient, study finds: ‘Intrigue and optimism’on April 29, 2024 at 2:00 pm
Vitamin D could be a surprise weapon against cancer, new research suggests.A study of mice published in the journal Science last week found that eating a diet rich in vitamin D changed the gut ...
- Pre-Ketone Supplement With Immunotherapy Shows Promise for Prostate Cancer in Miceon April 29, 2024 at 1:46 am
Adding a pre-ketone supplement – a component of a high-fat, low-carb ketogenic diet – to a type of cancer therapy in a laboratory setting was highly effective for treating prostate cancer.
via Bing News